9 results on '"Liboni C"'
Search Results
2. Administration of human msc?derived extracellular vesicles for the treatment of primary sclerosing cholangitis: Preclinical data in mdr2 knockout mice
- Author
-
Angioni, R, Calì, B, Vigneswara, V, Crescenzi, M, Merino Rodriguez, Ana, Sánchez?rodríguez, R, Liboni, C, Hoogduijn, Martin, Newsome, PN, Muraca, M, Russo, FP, Viola, A, Angioni, R, Calì, B, Vigneswara, V, Crescenzi, M, Merino Rodriguez, Ana, Sánchez?rodríguez, R, Liboni, C, Hoogduijn, Martin, Newsome, PN, Muraca, M, Russo, FP, and Viola, A
- Published
- 2020
3. On the leading edge of the process control world
- Author
-
Liboni, C., primary and De Lacerda, C., additional
- Published
- 1996
- Full Text
- View/download PDF
4. Platelets favor the outgrowth of established metastases.
- Author
-
Garcia-Leon MJ, Liboni C, Mittelheisser V, Bochler L, Follain G, Mouriaux C, Busnelli I, Larnicol A, Colin F, Peralta M, Osmani N, Gensbittel V, Bourdon C, Samaniego R, Pichot A, Paul N, Molitor A, Carapito R, Jandrot-Perrus M, Lefebvre O, Mangin PH, and Goetz JG
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Female, Mice, Inbred C57BL, Blood Platelets metabolism, Blood Platelets drug effects, Neoplasm Metastasis, Platelet Membrane Glycoproteins metabolism, Platelet Membrane Glycoproteins genetics
- Abstract
Despite abundant evidence demonstrating that platelets foster metastasis, anti-platelet agents have low therapeutic potential due to the risk of hemorrhages. In addition, whether platelets can regulate metastasis at the late stages of the disease remains unknown. In this study, we subject syngeneic models of metastasis to various thrombocytopenic regimes to show that platelets provide a biphasic contribution to metastasis. While potent intravascular binding of platelets to tumor cells efficiently promotes metastasis, platelets further support the outgrowth of established metastases via immune suppression. Genetic depletion and pharmacological targeting of the glycoprotein VI (GPVI) platelet-specific receptor in humanized mouse models efficiently reduce the growth of established metastases, independently of active platelet binding to tumor cells in the bloodstream. Our study demonstrates therapeutic efficacy when targeting animals bearing growing metastases. It further identifies GPVI as a molecular target whose inhibition can impair metastasis without inducing collateral hemostatic perturbations., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
5. Extracellular Vesicles From Mesenchymal Umbilical Cord Cells Exert Protection Against Oxidative Stress and Fibrosis in a Rat Model of Bronchopulmonary Dysplasia.
- Author
-
Bisaccia P, Magarotto F, D'Agostino S, Dedja A, Barbon S, Guidolin D, Liboni C, Angioni R, De Lazzari G, Caicci F, Viola A, Jurga M, Kundrotas G, Stevens D, Mancuso D, Gramegna E, Seitaj B, Kashyap R, De Vos B, Macchi V, Baraldi E, Porzionato A, De Caro R, Muraca M, and Pozzobon M
- Subjects
- Infant, Newborn, Rats, Animals, Humans, Tissue Distribution, Fibrosis, Umbilical Cord metabolism, Oxidative Stress, Collagen metabolism, Disease Models, Animal, Bronchopulmonary Dysplasia therapy, Hyperoxia, Extracellular Vesicles metabolism, Mesenchymal Stem Cells metabolism
- Abstract
Oxidative stress and fibrosis are important stress responses that characterize bronchopulmonary dysplasia (BPD), a disease for which only a therapy but not a cure has been developed. In this work, we investigated the effects of mesenchymal stromal cells-derived extracellular vesicles (MSC-EVs) on lung and brain compartment in an animal model of hyperoxia-induced BPD. Rat pups were intratracheally injected with MSC-EVs produced by human umbilical cord-derived MSC, following the Good Manufacturing Practice-grade (GMP-grade). After evaluating biodistribution of labelled MSC-EVs in rat pups left in normoxia and hyperoxia, oxidative stress and fibrosis investigation were performed. Oxidative stress protection by MSC-EVs treatment was proved both in lung and in brain. The lung epithelial compartment ameliorated glycosaminoglycan and surfactant protein expression in MSC-EVs-injected rat pups compared to untreated animals. Pups under hyperoxia exhibited a fibrotic phenotype in lungs shown by increased collagen deposition and also expression of profibrotic genes. Both parameters were reduced by treatment with MSC-EVs. We established an in vitro model of fibrosis and another of oxidative stress, and we proved that MSC-EVs suppressed the induction of αSMA, influencing collagen deposition and protecting from the oxidative stress. In conclusion, intratracheal administration of clinical-grade MSC-EVs protect from oxidative stress, improves pulmonary epithelial function, and counteracts the development of fibrosis. In the future, MSC-EVs could represent a new cure to prevent the development of BPD., (© The Author(s) 2023. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
6. CD28 and chemokine receptors: Signalling amplifiers at the immunological synapse.
- Author
-
Molon B, Liboni C, and Viola A
- Subjects
- Membrane Microdomains metabolism, Receptors, Chemokine metabolism, Signal Transduction physiology, CD28 Antigens, Immunological Synapses metabolism
- Abstract
T cells are master regulators of the immune response tuning, among others, B cells, macrophages and NK cells. To exert their functions requiring high sensibility and specificity, T cells need to integrate different stimuli from the surrounding microenvironment. A finely tuned signalling compartmentalization orchestrated in dynamic platforms is an essential requirement for the proper and efficient response of these cells to distinct triggers. During years, several studies have depicted the pivotal role of the cytoskeleton and lipid microdomains in controlling signalling compartmentalization during T cell activation and functions. Here, we discuss mechanisms responsible for signalling amplification and compartmentalization in T cell activation, focusing on the role of CD28, chemokine receptors and the actin cytoskeleton. We also take into account the detrimental effect of mutations carried by distinct signalling proteins giving rise to syndromes characterized by defects in T cell functionality., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Molon, Liboni and Viola.)
- Published
- 2022
- Full Text
- View/download PDF
7. Arrhythmogenic Cardiomyopathy Is a Multicellular Disease Affecting Cardiac and Bone Marrow Mesenchymal Stromal Cells.
- Author
-
Scalco A, Liboni C, Angioni R, Di Bona A, Albiero M, Bertoldi N, Fadini GP, Thiene G, Chelko SP, Basso C, Viola A, Mongillo M, and Zaglia T
- Abstract
Arrhythmogenic cardiomyopathy (AC) is a familial cardiac disorder at high risk of arrhythmic sudden death in the young and athletes. AC is hallmarked by myocardial replacement with fibro-fatty tissue, favoring life-threatening cardiac arrhythmias and contractile dysfunction. The AC pathogenesis is unclear, and the disease urgently needs mechanism-driven therapies. Current AC research is mainly focused on 'desmosome-carrying' cardiomyocytes, but desmosomal proteins are also expressed by non-myocyte cells, which also harbor AC variants, including mesenchymal stromal cells (MSCs). Consistently, cardiac-MSCs contribute to adipose tissue in human AC hearts. We thus approached AC as a multicellular disorder, hypothesizing that it also affects extra-cardiac bone marrow (BM)-MSCs. Our results show changes in the desmosomal protein profile of both cardiac- and BM- MSCs, from desmoglein-2 ( Dsg2 )-mutant mice, accompanied with profound alterations in cytoskeletal organization, which are directly caused by AC-linked DSG2 downregulation. In addition, AC BM-MSCs display increased proliferation rate, both in vitro and in vivo, and, by using the principle of the competition homing assay, we demonstrated that mutant circulating BM-MSCs have increased propensity to migrate to the AC heart. Taken altogether, our results indicate that cardiac- and BM- MSCs are additional cell types affected in Dsg2 -linked AC, warranting the novel classification of AC as a multicellular and multiorgan disease.
- Published
- 2021
- Full Text
- View/download PDF
8. Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice.
- Author
-
Angioni R, Calì B, Vigneswara V, Crescenzi M, Merino A, Sánchez-Rodríguez R, Liboni C, Hoogduijn MJ, Newsome PN, Muraca M, Russo FP, and Viola A
- Subjects
- Alanine Transaminase blood, Alkaline Phosphatase blood, Animals, Bile Acids and Salts blood, Cholangitis, Sclerosing blood, Cholangitis, Sclerosing genetics, Cholangitis, Sclerosing pathology, Disease Models, Animal, Extracellular Vesicles genetics, Gene Expression Regulation drug effects, Granulocytes pathology, Humans, Inflammation blood, Inflammation genetics, Inflammation pathology, Liver pathology, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells metabolism, Mice, Mice, Knockout, T-Lymphocytes pathology, Vascular Cell Adhesion Molecule-1 genetics, ATP-Binding Cassette Sub-Family B Member 4, ATP Binding Cassette Transporter, Subfamily B genetics, Cholangitis, Sclerosing therapy, Inflammation therapy, Liver metabolism
- Abstract
Primary Sclerosing Cholangitis (PSC) is a progressive liver disease for which there is no effective medical therapy. PSC belongs to the family of immune-mediated biliary disorders and it is characterized by persistent biliary inflammation and fibrosis. Here, we explored the possibility of using extracellular vesicles (EVs) derived from human, bone marrow mesenchymal stromal cells (MSCs) to target liver inflammation and reduce fibrosis in a mouse model of PSC. Five-week-old male FVB.129P2-Abcb
4tm1Bor mice were intraperitoneally injected with either 100 µL of EVs (± 9.1 × 109 particles/mL) or PBS, once a week, for three consecutive weeks. One week after the last injection, mice were sacrificed and liver and blood collected for flow cytometry analysis and transaminase quantification. In FVB.129P2-Abcb4tm1Bor mice, EV administration resulted in reduced serum levels of alkaline phosphatase (ALP), bile acid (BA), and alanine aminotransferase (ALT), as well as in decreased liver fibrosis. Mechanistically, we observed that EVs reduce liver accumulation of both granulocytes and T cells and dampen VCAM-1 expression. Further analysis revealed that the therapeutic effect of EVs is accompanied by the inhibition of NFkB activation in proximity of the portal triad. Our pre-clinical experiments suggest that EVs isolated from MSCs may represent an effective therapeutic strategy to treat patients suffering from PSC.- Published
- 2020
- Full Text
- View/download PDF
9. CD73 + extracellular vesicles inhibit angiogenesis through adenosine A 2B receptor signalling.
- Author
-
Angioni R, Liboni C, Herkenne S, Sánchez-Rodríguez R, Borile G, Marcuzzi E, Calì B, Muraca M, and Viola A
- Abstract
Pathological angiogenesis is a hallmark of several conditions including eye diseases, inflammatory diseases, and cancer. Stromal cells play a crucial role in regulating angiogenesis through the release of soluble factors or direct contact with endothelial cells. Here, we analysed the properties of the extracellular vesicles (EVs) released by bone marrow mesenchymal stromal cells (MSCs) and explored the possibility of using them to therapeutically target angiogenesis. We demonstrated that in response to pro-inflammatory cytokines, MSCs produce EVs that are enriched in TIMP-1, CD39 and CD73 and inhibit angiogenesis targeting both extracellular matrix remodelling and endothelial cell migration. We identified a novel anti-angiogenic mechanism based on adenosine production, triggering of A
2B adenosine receptors, and induction of NOX2-dependent oxidative stress within endothelial cells. Finally, in pilot experiments, we exploited the anti-angiogenic EVs to inhibit tumour progression in vivo . Our results identify novel pathways involved in the crosstalk between endothelial and stromal cell and suggest new therapeutic strategies to target pathological angiogenesis., (© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.